Skip to main content

Select Drug Profiles

Select Drug Profiles, Payers' Guide

Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis

Select Drug Profiles, Payers' Guide

Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis

Select Drug Profiles, Payers' Guide

Shingrix (Zoster Vaccine Recombinant) a New Vaccine Approved for Herpes Zoster Prevention in Older Adults

Select Drug Profiles, Payers' Guide

Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer

Select Drug Profiles, Payers' Guide

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Select Drug Profiles, Payers' Guide

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Select Drug Profiles, Payers' Guide

Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation

Select Drug Profiles, Payers' Guide

Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease

Select Drug Profiles, Payers' Guide

Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Lung Cancer, Select Drug Profiles, Payers' Guide

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

8
9
10
11
12
13
14

Page 11 of 20
Results 101 - 110 of 200